Hong Kong's New Narrative: The Capital Magnetism and Innovation Momentum in Medical Advancement

Currently serves as Executive Director and General Manager of Guangzhou Shangjun Investment Consulting Co., Ltd., and concurrently holds the positions of Standing Committee Member of the Medical Innovation and Translation Expert Committee of the Guangdong Medical Association, and Executive Secretary-General of the China-Europe Science and Technology Investment Promotion Association.

Focusing on investment and ecosystem development in the healthcare industry, we have established an international financial innovation platform for life sciences. This one-stop platform facilitates the industrial commercialization of innovative scientific and technological achievements originating from universities, research institutes, and medical institutions, integrating consulting, investment, in-depth project services, and resource integration. We link and collaborate closely with innovative enterprises, investment institutions, medical organizations, service providers, think tanks, and government bodies, committed to building a globally leading life science ecosystem.

Dr. Kwong has extensive experience in the commercialization of innovative technologies and startup incubation. He is currently responsible for coordinating the development of the ecosystem at the Hong Kong-Shenzhen Innovation and Technology Park (HSITP). Located in the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone, the park is closely connected with its Shenzhen counterpart, aiming to accelerate innovation and technology development by leveraging the flow of talent, capital, samples, and information between the two cities. Previously, Dr. Kwong served as the Head of the Biotechnology and Entrepreneurship Support Division at the Office of Knowledge Transfer of the Hong Kong University of Science and Technology (HKUST), a cradle for many successful tech entrepreneurs. He led and oversaw more than 50 tech companies spanning various technological fields, including healthcare, fintech, materials science, electronics, and software. These tech startups collectively secured over USD 50 million in financing or merged with Fortune 500 companies.

M.D., Physician. He earned his bachelor’s, master’s, and doctoral degrees in Clinical Medicine and Stomatology from Shanghai Jiao Tong University. Currently, he serves as a Postdoctoral Research Fellow at the Centre for Advanced Biomedical Instrumentation of The University of Hong Kong, where he is responsible for business development, clinical collaborations, and investment and financing affairs. He also holds the positions of Executive Director (Medical Affairs) at the Hong Kong Top Talent Pass Services Association and Medical Advisor to the Hong Kong Biotechnology Organization. Early in his career, he completed standardized residency training at a top-tier tertiary hospital in Shanghai, accumulating extensive clinical experience. Subsequently, he interned at a renowned healthcare investment firm, participating in the analysis and evaluation of projects across multiple frontier medical sectors in both primary and secondary markets. With a multidisciplinary professional background spanning clinical medicine, basic scientific research, and healthcare investment and consulting, he also holds Hong Kong licenses for fund and securities practitioners.

Mr. Chen holds a Master of Science degree in Biopharmaceutical R&D and Industrialization from The Hong Kong Polytechnic University. Prior to joining Gobi Partners, he worked at WuXi Biologics, where he accumulated extensive experience in the execution and implementation of Chemistry, Manufacturing, and Controls (CMC) within the biopharmaceutical sector. As an ecosystem partner for universities including The Hong Kong Polytechnic University, Mr. Chen has frequently served as a judge for events such as TSSSU and participated in entrepreneurship courses to support the growth of university-incubated startups. Leveraging his solid industrial background, Mr. Chen currently focuses on early-stage investment opportunities in frontier fields such as life sciences, healthcare, and brain-computer interfaces. His representative investment cases include Gestala, AilsynBio, and Future Brain Rhythm.